An Entity of Type: Antigen115037339, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. Today, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921. About three out of every 10,000 people who get the vaccine experience side effects, which are usually minor except in severely immuno-depressed individuals. While BCG immunization provides fairly effective protection for infants and young children (including defence against TB meningitis and miliary TB), its efficacy in adults is variable, ranging from 0% to 80%. Several variables have been considered as responsible for the varying outcomes. Demand for TB immunotherapy advancement exists

Property Value
dbo:abstract
  • Tuberkuloseimpfstoffe (TB-Impfstoffe) sind Impfstoffe zur Vorbeugung von Tuberkulose. Die Immuntherapie zur Tuberkuloseabwehr wurde erstmals 1890 von Robert Koch vorgeschlagen. Der einzige heute gebräuchliche wirksame Tuberkuloseimpfstoff ist der Bacillus Calmette-Guérin (BCG)-Impfstoff, der erstmals 1921 beim Menschen eingesetzt wurde. Bei etwa drei von 10.000 Personen, die den Impfstoff erhalten, treten Nebenwirkungen auf, die in der Regel geringfügig sind, außer bei schwer immungeschwächten Personen. Während die BCG-Impfung bei Säuglingen und Kleinkindern einen recht wirksamen Schutz bietet (einschließlich Schutz vor TB-Meningitis und Miliartuberkulose), ist die Wirksamkeit bei Erwachsenen unterschiedlich, sie reicht von 0 % bis 80 %. Für die unterschiedlichen Ergebnisse werden mehrere Variablen verantwortlich gemacht. Die Nachfrage nach einer Verbesserung der TB-Immuntherapie besteht, weil die Krankheit zunehmend arzneimittelresistent geworden ist. (de)
  • Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. Today, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921. About three out of every 10,000 people who get the vaccine experience side effects, which are usually minor except in severely immuno-depressed individuals. While BCG immunization provides fairly effective protection for infants and young children (including defence against TB meningitis and miliary TB), its efficacy in adults is variable, ranging from 0% to 80%. Several variables have been considered as responsible for the varying outcomes. Demand for TB immunotherapy advancement exists because the disease has become increasingly drug-resistant. Other tuberculosis vaccines are at various stages of development, including: * MVA85A * rBCG30 * 72F fusion protein * MTBVAC New vaccines are being developed by the Tuberculosis Vaccine Initiative, including and . (en)
dbo:wikiPageID
  • 4958015 (xsd:integer)
dbo:wikiPageLength
  • 7576 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1118677179 (xsd:integer)
dbo:wikiPageWikiLink
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Tuberkuloseimpfstoffe (TB-Impfstoffe) sind Impfstoffe zur Vorbeugung von Tuberkulose. Die Immuntherapie zur Tuberkuloseabwehr wurde erstmals 1890 von Robert Koch vorgeschlagen. Der einzige heute gebräuchliche wirksame Tuberkuloseimpfstoff ist der Bacillus Calmette-Guérin (BCG)-Impfstoff, der erstmals 1921 beim Menschen eingesetzt wurde. Bei etwa drei von 10.000 Personen, die den Impfstoff erhalten, treten Nebenwirkungen auf, die in der Regel geringfügig sind, außer bei schwer immungeschwächten Personen. Während die BCG-Impfung bei Säuglingen und Kleinkindern einen recht wirksamen Schutz bietet (einschließlich Schutz vor TB-Meningitis und Miliartuberkulose), ist die Wirksamkeit bei Erwachsenen unterschiedlich, sie reicht von 0 % bis 80 %. Für die unterschiedlichen Ergebnisse werden mehrere (de)
  • Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. Today, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921. About three out of every 10,000 people who get the vaccine experience side effects, which are usually minor except in severely immuno-depressed individuals. While BCG immunization provides fairly effective protection for infants and young children (including defence against TB meningitis and miliary TB), its efficacy in adults is variable, ranging from 0% to 80%. Several variables have been considered as responsible for the varying outcomes. Demand for TB immunotherapy advancement exists (en)
rdfs:label
  • Tuberculosis vaccines (en)
  • Tuberkuloseimpfstoff (de)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:academicDiscipline of
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is dbp:fields of
is rdfs:seeAlso of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License